TUCSON, Ariz. – HTG Molecular Diagnostics, provider of molecular technology solutions, today announced the appointment of Debra Gordon, Ph.D., J.D., to Vice President, Chief Legal Counsel. This announcement comes on the heels of HTG announcing SR One, the corporate venture capital arm of GlaxoSmithKline, joined the company’s investment syndicate.

Dr. Gordon will guide the development and execution of the company’s intellectual property strategy, lead human resources activities and advise on all legal matters. She brings diverse legal experience as a business transactional and intellectual property attorney at leading U.S. and international law firms. Prior to joining HTG, Dr. Gordon served as General Counsel and Head, Patent Legal for Ventana Medical Systems.

“Dr. Gordon’s extensive legal practice is supported by her strong scientific background making her an ideal asset to our senior management team as HTG Molecular Diagnostics continues to grow and expand our molecular diagnostics business,” said TJ Johnson, chief executive officer, HTG Molecular Diagnostics.

Dr. Gordon received her J.D. with honors from the University of Arizona James E. Rogers College of Law, and her Ph.D. from the University of Arizona College of Medicine.

About HTG Molecular Diagnostics

HTG Molecular Diagnostics is a leading provider of molecular-based technology solutions for gene expression profiling, miRNA, siRNA and mRNA measurement for translational medicine and diagnostic applications. The Company’s qNPA™ molecular technology platform is well-suited for reliably detecting small, yet important, changes in gene expression levels in a variety of sample types. Privately-held HTG is based in Tucson, Arizona. Additional information is available at www.htgmolecular.com.